{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-022046","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.529041+00:00","generated_at":"2026-06-05T09:13:30.657263+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcellx posts Q4 net income of $20.5M, cash $729.2M, expands Kite partnership","bullets":["Q4 2023 net income $20.5M vs net loss $39.0M in Q4 2022; full-year net loss narrowed to $70.7M from $188.7M.","Cash, cash equivalents and marketable securities $729.2M; cash runway extended into 2027.","Collaboration revenue from Kite partnership: $63.1M in Q4 and $110.3M full year, both vs zero.","Kite partnership expanded with $200M equity investment at $61.68/share and $85M upfront cash, plus co-development of anito-cel for lymphomas.","Phase 1 anito-cel data: 100% ORR, 76% CR/sCR (29/38 patients), no delayed neurotoxicity, median DOR/PFS/OS not reached."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-022046","json":"https://secwatch.observer/filing/0000950170-24-022046.json","markdown":"https://secwatch.observer/filing/0000950170-24-022046.md","text":"https://secwatch.observer/filing/0000950170-24-022046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000095017024022046/0000950170-24-022046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000095017024022046/aclx-20240228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T09:13:30.657263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf0f4cb94307fe79c3cb5be782f6f803d71a6fae","claim":"Arcellx, Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $63.1 million, net income $20.5 million.","evidence_excerpt":"million. Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2027. Collaboration revenue: Collaboration revenue was $63.1 million and zero for the quarters ended December 31, 2023 and 2022, respectively. Collaboration revenue was $110.3 million and zero for the twelve months ended December 31, 2023 and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1786205/000095017024022046/0000950170-24-022046-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$63.1 million"},{"label":"Net income","value":"$20.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}